Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI3506 in moderate to severe COPD with chronic bronchitis
NL-OMON55071Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing MEDI3506 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in pre-bronchodilator FEV1. Started Aug 2021; status: active, not recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON55071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55071.